Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Renal cell carcinoma cytotoxicity enhanced by histone deacetylase inhibitors
July 14th, 2006
Recent research from the United States has documented the enhancement of Ad5- tumor necrosis factor (TNF) family member TNF-related apoptosis-inducing ligand (TRAIL) cytotoxicity against renal cell carcinoma (RCC) with histone deacetylase inhibitors. "RCC will cause greater than 12,000 deaths in the United States this year. The lack of effective therapy for disseminated RCC has stimulated the search for novel treatments including immunotherapeutic strategies, but poor therapeutic responses and marked toxicity have limited their use. "The (TRAIL)/Apo-2L induces apoptosis in various tumor cell types, while having little cytotoxicity against normal...
Source: Genomics & Genetics Weekly (2006-07-14)
|
